Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
$2.71
-$0.02(-0.92%)
At close: 4:00 PM EST
$2.71
-$0.02(-0.92%)
Day’s Range― - ―
52-Week Range$0.69 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)7.44M
Market Cap
$627.70M
Enterprise Value$706.58M
Total Cash (Recent Filing)$86.06M
Total Debt (Recent Filing)$146.45M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Nov 06, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding231,622,820
10 Day Avg. Volume5,100,150
30 Day Avg. Volume7,435,090
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.06
Price to Sales (P/S)1.24
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda-28.74
Forecast
1Y Price Target
$6.92Price Target Upside155.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEsperion’s partner Otsuka Pharmaceuticals announced that BDA met the primary endpoint of cholesterol lowering in a Phase 3 trial, demonstrating significant LDL-C reductions compared to placebo.
Japanese Market EntryEsperion's entry into the Japanese market represents a major step forward as Japan is one of the top three global markets for cardiovascular prevention.
Market ExpansionRegulatory approval for NEXLETOL in Japan marks a key milestone in commercial expansion, allowing Esperion to receive milestone payments and royalties based on net sales achievements by partner Otsuka Pharmaceuticals.
Bears Say
Stock RatingMaintain underperform rating due to the US growth concerns and the stock price objective of $1.60.
US Growth ChallengesThe trajectory of BA's uptake in the US is worrisome this early in the re-launch when uptake should be inflecting.
US Market ConcernsInvestor debate remains focused on the US, where despite recognizing BA’s value, there are concerns about the potential of a broad role and uptake appears to be slowing.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $627.70M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Nov 06, 2025 which is in 9 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Aug 11, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.146 by $0.126.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is 0.02.
How many shares outstanding does Esperion have?
Esperion has 231,622,820 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.146. Following the earnings report the stock price went down -1.604%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.92 (155.35% Upside)
$6.92 (155.35% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 558.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.49%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company operates primarily in the pharmaceutical sector, concentrating on cardiovascular diseases. Esperion's core products include bempedoic acid and its combination therapy with ezetimibe, aimed at providing effective solutions for individuals who are unable to achieve their cholesterol goals with traditional statin therapy.
ESPR Company Deck
ESPR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Esperion's robust financial performance with significant revenue growth and strategic achievements, such as achieving operating income for the first time and strong international partnerships. While there were some concerns about collaboration revenue and milestone payments, the positive aspects of the company's growth and strategic initiatives significantly outweigh the challenges.View all ESPR earnings summariesESPR Stock 12 Month Forecast
Average Price Target
$6.92
▲(155.35% Upside)
Technical Analysis
Ownership Overview
1.36% Insiders
10.63% Mutual Funds
0.05% Other Institutional Investors
79.56% Public Companies and
Individual Investors